00:45 , Jan 12, 2017 |  BC Week In Review  |  Clinical News

Onapristone: Ph II halted

Arno said it halted enrollment in the Phase II portion of an open-label, U.K. Phase I/II trial evaluating twice-daily onapristone plus Zytiga abiraterone acetate after the company determined further enrollment was not justified based on...
08:00 , Nov 2, 2015 |  BC Week In Review  |  Clinical News

Arno preclinical data

In human CF macrophages, Arno said AR-13 in combination with broad-spectrum antibiotics synergistically reduced antibiotic-resistant Burkholderia cenocepacia burden. In CF neutrophils, AR-13 alone significantly reduced Pseudomonas aeruginosa burden by 70%. Data were presented at the...
07:00 , May 11, 2015 |  BC Week In Review  |  Clinical News

AR-12 regulatory update

The European Commission granted Orphan Drug designation to AR-12 from Arno to treat cryptococcosis and tularemia. The small molecule 3-phosphoinositide dependent protein kinase-1 (PDPK1) inhibitor is in preclinical testing for the indications. It has completed...
07:00 , Sep 11, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Rett syndrome DNA (cytosine-5-)- methyltransferase 1 (DNMT1); 3-phosphoinositide dependent protein kinase-1 (PDPK1); aurora kinase A (AURKA; aurora-A); X inactive specific transcript (XIST); methyl CpG binding...
07:00 , Oct 17, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Melanoma 3-Phosphoinositide-dependent protein kinase-1 (PDPK1); BRAF Studies in patient tumor samples and mice suggest PDPK1 inhibitors could help treat melanoma. In...
07:00 , Sep 19, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD); neurology 3-Phosphoinositide-dependent protein kinase-1 (PDPK1) Mouse and cell culture studies suggest inhibiting PDPK1 activity could help treat AD and prion-associated diseases. In...
07:00 , Mar 21, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Pancreatic cancer K-Ras; 3-phosphoinositide-dependent protein kinase-1 (PDPK1) Mouse studies suggest inhibiting PDPK1 could help prevent mutant K-Ras-driven pancreatic ductal adenocarcinomas (PDACs)....
08:00 , Dec 9, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Colorectal cancer Mammalian target of rapamycin (mTOR; FRAP; RAFT1); protein phosphatase 2 regulatory subunit Bβ (PPP2R2B); 3-phosphoinositide-dependent protein kinase-1 (PDPK1); c-Myc Studies in mice and...
07:00 , Sep 7, 2009 |  BC Week In Review  |  Clinical News

AR-12: Phase I started

Arno began an open-label, dose-escalation, U.S. and European Phase I trial to evaluate oral AR-12 given for 28 consecutive days in up to 50 patients. Arno Therapeutics Inc. (OTCBB:ARNI), Fairfield, N.J.   Product: AR-12 (formerly...
07:00 , Jun 9, 2008 |  BC Week In Review  |  Company News

Arno, Laurier International Inc. deal

Arno acquired public shell company Laurier for $22.6 million in a reverse merger. Arno also raised $18 million in a private placement. Arno will retain its headquarters and management and will trade under the symbol...